Goldman Sachs tips ResMed shares to rocket 30% to a record high
The broker is feeling very bullish about the sleep disorder treatment company. The post Goldman Sachs tips ResMed shares to ...
Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Balanced Outlook on ResMed: Strong Execution and Innovations Offset by Valuation Concerns and Market Challenges
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...